P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY

• J. Kuruvilla,
• P. Armand,
• A. F. Herrera,
• V. Ribrag,
• P. Brice,
• C. Thieblemont,
• B. Von Tresckow,
• E. Kim,
• P. Marinello,
• S. Chakraborty,
• R. Orlowski,
• P. L. Zinzani

Affiliations

J. Kuruvilla

1 Princess Margaret Cancer Centre, Toronto, Canada

P. Armand

2 Dana-Farber Cancer Institute, Harvard Medical School, Boston

A. F. Herrera

3 City of Hope Medical Center, Duarte, United States of America

V. Ribrag

4 Institut Gustave Roussy, Villejuif

P. Brice

5 APHP, Hôpital Saint-Louis, Hemato-Oncologie, Université de Paris, Paris, France

C. Thieblemont

5 APHP, Hôpital Saint-Louis, Hemato-Oncologie, Université de Paris, Paris, France

B. Von Tresckow

6 University Hospital Cologne, University of Cologne, and West German Cancer Center, Essen University Hospital, University of Duisburg-Essen, Essen, Germany

E. Kim

7 Merck & Co., Inc., Kenilworth, United States of America

P. Marinello

7 Merck & Co., Inc., Kenilworth, United States of America

S. Chakraborty

7 Merck & Co., Inc., Kenilworth, United States of America

R. Orlowski

7 Merck & Co., Inc., Kenilworth, United States of America

P. L. Zinzani

8 IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy